Joel Isaacson & Co’s Idexx Laboratories IDXX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$367K Hold
698
0.01% 348
2026
Q1
$392K Sell
698
-125
-15% -$80.2K 0.01% 319
2025
Q4
$557K Sell
823
-50
-6% -$34.1K 0.02% 270
2025
Q3
$558K Hold
873
0.02% 257
2025
Q2
$468K Hold
873
0.02% 266
2025
Q1
$367K Hold
873
0.02% 282
2024
Q4
$361K Hold
873
0.02% 271
2024
Q3
$441K Sell
873
-579
-40% -$281K 0.02% 239
2024
Q2
$707K Hold
1,452
0.04% 164
2024
Q1
$784K Hold
1,452
0.04% 155
2023
Q4
$806K Hold
1,452
0.05% 149
2023
Q3
$635K Sell
1,452
-100
-6% -$49.9K 0.04% 161
2023
Q2
$779K Hold
1,552
0.05% 143
2023
Q1
$776K Hold
1,552
0.06% 139
2022
Q4
$633K Buy
1,552
+723
+87% +$281K 0.05% 147
2022
Q3
$270K Hold
829
0.02% 250
2022
Q2
$291K Hold
829
0.02% 240
2022
Q1
$404K Hold
829
0.03% 209
2021
Q4
$546K Buy
829
+279
+51% +$175K 0.04% 174
2021
Q3
$342K Buy
+550
New +$370K 0.03% 233
2014
Q1
Sell
-120
Closed -$6K 575
2013
Q4
$6K Hold
120
﹤0.01% 454
2013
Q3
$6K Hold
120
﹤0.01% 436
2013
Q2
$5K Buy
+120
New +$5.24K ﹤0.01% 411

Other funds holding IDXX

Joel Isaacson & Co's IDXX Position: Q2 2026 in Review

Joel Isaacson & Co held its Idexx Laboratories (IDXX) position steady in Q2 2026 at 698 shares worth $367K. The position accounts for 0.01% of the portfolio, ranked #348.

Joel Isaacson & Co first reported a position in IDXX in Q2 2013 and has held it in 23 quarters since. The position peaked at $806K in Q4 2023. 715 funds tracked by Wall St. Rank hold IDXX as of Q2 2026.

  • Joel Isaacson & Co held 698 shares of Idexx Laboratories worth $367K as of Q2 2026.
  • Joel Isaacson & Co left its Idexx Laboratories share count unchanged in Q2 2026.
  • Idexx Laboratories made up 0.01% of Joel Isaacson & Co's portfolio in Q2 2026, its #348 holding.
  • Joel Isaacson & Co first reported a position in Idexx Laboratories in Q2 2013 and has held it in 23 quarters since.
  • Joel Isaacson & Co's Idexx Laboratories position peaked at $806K in Q4 2023.
  • 715 funds tracked by Wall St. Rank held Idexx Laboratories as of Q2 2026.

Based on Joel Isaacson & Co's 13F filing for Q2 2026, filed 4 Aug 2026.